HCM
ACET icon

Hollencrest Capital Management’s Adicet Bio ACET Stock Holding History

Hollencrest Capital Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-250
Closed -$2.1K – 1223
2025
Q4 		$2.1K Buy
250
+125
+100% +$1.38K ﹤0.01% 1010
2025
Q3 		$1.62K Hold
125
– – ﹤0.01% 1009
2025
Q2 		$1.22K Buy
125
+69
+123% +$728 ﹤0.01% 1009
2025
Q1 		$680 Hold
56
– – ﹤0.01% 1038
2024
Q4 		$866 Buy
56
+37
+195% +$698 ﹤0.01% 1076
2024
Q3 		$432 Hold
19
– – ﹤0.01% 1051
2024
Q2 		$363 Hold
19
– – ﹤0.01% 1036
2024
Q1 		$705 Hold
19
– – ﹤0.01% 981
2023
Q4 		$567 Hold
19
– – ﹤0.01% 974
2023
Q3 		$411 Hold
19
– – ﹤0.01% 1009
2023
Q2 		$729 Hold
19
– – ﹤0.01% 1042
2023
Q1 		$1.73K Buy
+19
New +$2.38K ﹤0.01% 976

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Hollencrest Capital Management's ACET Position: Q1 2026 in Review

Hollencrest Capital Management sold out of Adicet Bio (ACET) in Q1 2026, closing a stake of 250 shares — an estimated $2.1K sold.

Hollencrest Capital Management first reported a position in ACET in Q1 2023 and held it in 12 quarters. The position peaked at $2.1K in Q4 2025. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

  • Hollencrest Capital Management reported no remaining Adicet Bio position as of Q1 2026 after selling out during the quarter.
  • Hollencrest Capital Management sold 250 Adicet Bio shares in Q1 2026, an estimated $2.1K.
  • Hollencrest Capital Management first reported a position in Adicet Bio in Q1 2023 and held it in 12 quarters.
  • Hollencrest Capital Management's Adicet Bio position peaked at $2.1K in Q4 2025.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on Hollencrest Capital Management's 13F filing for Q1 2026, filed 7 May 2026.